{
    "id": 11670,
    "fullName": "EGFR Q791R",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR Q791R lies with the protein kinase domain of the Egfr protein (UniProt.org). Q791R has been demonstrated to confer resistance to some third generation EGFR inhibitors (PMID: 25948633), but has not been biochemically characterized and therefore, its effect on Egfr protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "Q791R",
    "createDate": "09/10/2015",
    "updateDate": "10/06/2019",
    "referenceTranscriptCoordinates": {
        "id": 135826,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55181381A>G",
        "cDna": "c.2372A>G",
        "protein": "p.Q791R",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3095,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11732,
                "profileName": "EGFR T790M EGFR Q791R EGFR L858R"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3097,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR L858R/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11732,
                "profileName": "EGFR T790M EGFR Q791R EGFR L858R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3096,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD9291 inhibited growth of transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11733,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR Q791R"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3094,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing an EGFR E746_A750del/EGFR T790M/EGFR Q791R triple mutation demonstrated resistance to Rociletinib (CO-1686) in culture (PMID: 25948633).",
            "molecularProfile": {
                "id": 11733,
                "profileName": "EGFR E746_A750del EGFR T790M EGFR Q791R"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3618,
                    "pubMedId": 25948633,
                    "title": "EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25948633"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 11731,
            "profileName": "EGFR Q791R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11732,
            "profileName": "EGFR T790M EGFR Q791R EGFR L858R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 11733,
            "profileName": "EGFR E746_A750del EGFR T790M EGFR Q791R",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135826,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55181381A>G",
            "cDna": "c.2372A>G",
            "protein": "p.Q791R",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}